Tadalafil Tablet
Product Images NDC 27241-123

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 27241-123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil-20mg (Tadalafil 20mg)

Label for Tadalafil Tablets, USP 20 mg oral tablets by Ajanta Pharma USA Inc. The package contains 60 tablets. The label includes dosage instructions, storage conditions, warnings, and manufacturing information indicating the product is made in India. A small image of an oval tablet with '20' imprinted is shown, along with barcode and NDC 27241-123-02.*

FDA Label Image

Tadalafil Fig1

A forest plot chart showing mean differences in blood pressure changes (systolic and diastolic, standing, supine, and ambulatory) for Tadalafil 20 mg and 10 mg coadministered with various drugs compared to placebo. The x-axis represents difference values from -20 to 20 mmHg, with confidence intervals displayed for each drug coadministration scenario.*

FDA Label Image

Tadalafil Fig2

A scatter plot with error bars titled 'Coadministered Drug Fold Change and 90% CI' showing the changes in AUC and Cmax of Tadalafil when taken with various CYP3A inhibitors, CYP3A inducers, antacids, and H2 antagonists. The x-axis represents change relative to Tadalafil alone, ranging from 0.0 to 5.0. Recommendations on dose adjustment or avoidance accompany each drug interaction.*

FDA Label Image

Tadalafil Fig3

A chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) and bleeding time, comparing coadministered drugs with drug alone. The chart includes various CYP substrates, oral contraceptives, and NSAIDs, with corresponding recommendations, all indicating no dose adjustment needed.*

FDA Label Image

Tadalafil Fig4

A line graph comparing mean change from baseline in meters over a 16-week period between placebo and Tadalafil 40 mg groups. The x-axis represents weeks (0, 4, 8, 12, 16), and the y-axis shows mean change from baseline in meters with error bars. Tadalafil shows increasing improvement over time relative to placebo, with statistical significance indicated at 8, 12, and 16 weeks.*

FDA Label Image

Tadalafil Fig5

A horizontal forest plot depicting placebo-adjusted mean changes in 6-minute walk distance (meters) with 95% confidence intervals for Tadalafil 40 mg versus placebo. The graph compares subgroups by bosentan use, PAH etiology, baseline walk distance, gender, age, and baseline WHO functional class, with subject counts for each. The plot shows variations in mean changes and confidence intervals across these categories.*

FDA Label Image

Tadalafil Fig6

A line chart depicting time to clinical worsening in days on the x-axis and percentage without clinical worsening on the y-axis, comparing Tadalafil 40 mg, Tadalafil 20 mg, and placebo groups. The chart shows the percentage of subjects without clinical worsening over approximately 150 days for each treatment group.*

FDA Label Image

Tadalafil_structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, showing its molecular framework with labeled atoms and bonds as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.